secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108876
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q2 2025 cash $296.3M; dosed first patient in SURF302 NMIBC trial
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $296.3M as of June 30, 2025; runway through at least 2027.
- Q2 net loss of $28.1M, vs $18.7M in Q2 2024; R&D expenses $24.3M (up from $18.0M).
- Dosed first patient in SURF302 Phase 2 study of dabogratinib for FGFR3-altered intermediate-risk NMIBC.
- BEACH301 Phase 2 achondroplasia study now enrolling safety sentinel cohort; dose first child expected 3Q 2025.
- Initial three-month complete response data from SURF302 expected in first half 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017025108876/0000950170-25-108876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017025108876/tyra-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer